SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.
Channel-tuning neuropathy Michael J. Haas doi:10.1038/scibx.2012.564 International researchers have shown that a methylglyoxal-scavenging peptide treated painful diabetic neuropathy in mice by preventing structural changes to a sodium channel in peripheral neurons. The team is seeking venture capital to spin out the findings into a new company. Full Text | PDF
Going to BAT Joanne Kotz doi:10.1038/scibx.2012.565 A Brigham and Women's Hospital team has identified an enzyme that regulates white adipose plasticity, whereas a University of Cambridge team has identified a secreted protein that activates brown fat. Testing the potential of these new targets for boosting or activating calorie-burning brown fat will require developing lead therapeutic molecules. Full Text | PDF
Reprogramming heart failure Kai-Jye Lou doi:10.1038/scibx.2012.566 UCSF and UT Southwestern researchers have shown that direct reprogramming of cardiac fibroblasts into cardiomyocyte-like cells is feasible in vivo and could promote the recovery of cardiac function after myocardial infarction. LoneStar Heart has exclusively licensed the UT Southwestern technology. Full Text | PDF
Sequencing human diversity Lev Osherovich doi:10.1038/scibx.2012.567 Two teams have generated extensive data on sequence variation in genes that encode drug targets. The next step is figuring out if—and how—the variants influence drug response and disease susceptibility. Full Text | PDF
Casein kinase 1ε (CSNK1E; CKI-ε); c-Myc (MYC) doi:10.1038/scibx.2012.568 In vitro and mouse studies identified MYC-associated genes including CSNK1E that could be targeted to treat MYC-amplified cancers. Full Text | PDF
Endometrial differential 3 (EDI3) doi:10.1038/scibx.2012.569 Patient sample and in vitro studies suggest inhibiting EDI3 could help treat cancer. Full Text | PDF
NADPH oxidase (NOX) doi:10.1038/scibx.2012.570 In vitro and mouse studies suggest inhibiting NOX could help treat cancer. Full Text | PDF
Peptidyl arginine deiminase type IV (PADI4) doi:10.1038/scibx.2012.571 In vitro and mouse studies suggest PADI4 inhibitors could help treat sarcoma and other cancers. Full Text | PDF
β-Catenin (CTNNB1); forkhead box O3 (FOXO3; FOXO3a); phosphoinositide 3-kinase (PI3K); protein kinase B (PKB; PKBA; AKT; AKT1) doi:10.1038/scibx.2012.572 Patient and cell studies suggest inhibiting wingless-type MMTV integration site (WNT) and CTNNB1 signaling could help prevent drug resistance in colon cancer. Full Text | PDF
FERM domain containing 4A (FRMD4A) doi:10.1038/scibx.2012.573 Patient sample and mouse studies suggest inhibiting FRMD4A could be used to treat head and neck squamous cell carcinoma (HNSCC). Full Text | PDF
Zinc and ring finger 3 (ZNRF3); ring finger protein 43 (RNF43) doi:10.1038/scibx.2012.574 An in vitro study identified two new components of the wingless-type MMTV integration site (WNT) signaling pathway that could be targeted to treat pancreatic cancer or trigger tissue regeneration. Full Text | PDF
Bone morphogenetic protein 8b (BMP8B) doi:10.1038/scibx.2012.575 A study in cell culture and in mice suggests BMP8B could act both peripherally and centrally to help treat obesity. Full Text | PDF
Resolvin D1 (RvD1); RvD5 doi:10.1038/scibx.2012.576 A study in mice suggests RvD1 and RvD5 could be useful for treating bacterial infections. Full Text | PDF
Claudin 5 (CLDN5) doi:10.1038/scibx.2012.578 Mouse studies suggest blocking CLDN5 in the brain could help relieve brain edema and help treat traumatic brain injury. Full Text | PDF
Leucine-rich repeat kinase 2 (LRRK2) doi:10.1038/scibx.2012.579 Computational and in vitro studies identified a LRRK2 inhibitor that could be optimized to treat PD. Full Text | PDF
Thrombomodulin (THBD; CD141) doi:10.1038/scibx.2012.580 In vitro and mouse studies suggest vitamin D–treated CD141+ dendritic cells (DCs) could induce immune tolerance and help treat GvHD. Full Text | PDF
Cellular assay for detection of immune responses triggered by aggregated antibody therapeutics doi:10.1038/scibx.2012.581 An in vitro assay using human peripheral blood mononuclear cells could help assess the immunogenic risk of aggregates formed by antibody therapeutics. Full Text | PDF
High throughput human leukocyte antigen (HLA) genotyping doi:10.1038/scibx.2012.582 A high throughput HLA sequencing method could help identify disease-associated alleles. Full Text | PDF
Screen of sequentially administered cancer therapeutics to identify new combination therapies doi:10.1038/scibx.2012.583 A screen of drug combinations could help identify new therapeutic combinations to help treat cancer. Full Text | PDF
Zinc finger nuclease (ZFN)-engineered human cell lines for probing the function of polypeptide N-acetylgalactosamine transferase (GalNAc) isoforms doi:10.1038/scibx.2012.584 ZFN-engineered human cell lines that express polypeptide GalNAc transferase isoforms could help identify the role those enzymes play in disease. Full Text | PDF
Generation of myeloid precursors from embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells doi:10.1038/scibx.2012.585 In vitro and mouse studies identified a method to differentiate ESCs and iPS cells into skeletal muscle cells to help treat muscular dystrophy. Full Text | PDF
In vivo reprogramming of cardiac fibroblasts into cardiomyocytes doi:10.1038/scibx.2012.586 In vivo conversion of cardiac fibroblasts into cardiomyocytes could help treat heart damage. Full Text | PDF
Genetic variation in drug target genes doi:10.1038/scibx.2012.587 A human genetic study suggests genetic variation in drug targets may influence patient disease susceptibility and drug response. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment